



Präklinische Resultate von Ralfinamide in einem Modell zentralen Schmerzes werden am 6. Internationalen Kongress der European Federation of IASP Chapters (EFIC) vorgestellt

Mailand, Italien, 3. September 2009 – Newron Pharmaceuticals S.p.A. („Newron“, SIX: NWRN), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt innovative Therapien für Erkrankungen des Zentralen Nervensystems (ZNS) und Schmerzen, gibt heute bekannt, dass positive Resultate einer präklinischen Studie in einem experimentellen Modell zentralen Schmerzes am 6. Internationalen Kongress der European Federation of IASP Chapters (EFIC), der vom 9. bis 12. September 2009 in Lissabon, Portugal, stattfindet, präsentiert werden.

Die Studie wurde von Professor Ze'ev Seltzer, Senior Canada Research Chair in Genetics of Pain, der Universität von Toronto, Kanada, geleitet. Das Poster mit dem Titel: "Oral ralfinamide suppresses autotomy following hindpaw deafferentation by multiple dorsal rhizotomies, a rat model of CNS-mediated spontaneous neuropathic pain" (Oral verabreichtes Ralfinamide unterdrückt die Autotomie nach einer Deafferentation der Hinterpfoten bei multipler dorsaler Rhizotomie – eine Studie an Ratten über das ZNS spontan vermitteltem neuropathischen Schmerz) wird an der Poster-Session am Donnerstag, 10. September 2009, von 16:00 bis 16:45, Abstrakt Nummer 314, vorgestellt werden.

Über Ralfinamide

Ralfinamide, eine einzigartige, neue chemische Substanz, entfaltet ihre potente schmerzlindernde Wirkung durch die Inhibition von Natriumkanälen, inkl. Nav. 1.7, N-Typ, Kalziumkanälen und NMDA Rezeptor. Ralfinamide ist zur Zeit in einer Phase-IIb/III-Studie in Patienten mit neuropathischen Schmerzen im unteren Rücken (Neuropathic Low Back Pain, NLBP).

Über Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A. (www.newron.com) ist ein biopharmazeutisches Unternehmen, das sich auf neuartige Therapien für Erkrankungen des Zentralen Nervensystems und Schmerzen konzentriert. Newron führt gemeinsam mit dem Partner Merck Serono, der die exklusiven weltweiten Rechte zur Entwicklung, Herstellung und Kommerzialisierung von Safinamide für die Behandlung von PD, Alzheimer-Krankheit und andere therapeutische Anwendungen hält, Phase-III-Studien mit Safinamide zur Behandlung von Parkinson durch.

Newron hat kürzlich SERENA, eine mögliche pivotale Studie mit Ralfinamide in Patienten mit neuropathischen Schmerzen im unteren Rücken (Neuropathic Low Back Pain, NLBP) initiiert. Es gibt bisher keine zugelassenen Medikamente für NLBP, eine Erkrankung, an der 55 Millionen Patienten in den USA, Europa und Japan leiden.

Newron ist in Bresso bei Mailand, Italien, domiziliert. Das Unternehmen ist an der SIX Swiss Exchange kotiert, Symbol NWRN.



Für weitere Informationen:

Medien	Investoren und Analysten
<p>Italien Luca Benatti - CEO Tel.: +39 02 6103 4 626 E-mail: pr@newron.com</p> <p>UK/Globale medien Julia Phillips Financial Dynamics Tel.: +44 (0) 20 7269 7187</p> <p>Schweiz Martin Meier-Pfister IRF Communications Tel.: +41 43 244 81 40</p>	<p>Stefan Weber - CFO Tel.: +39 02 6103 46 30 E-mail: ir@newron.com</p>

Important Notices

This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements.

By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions.

Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions.

Newron does not undertake any obligation to publicly up-date or revise forward looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed.

This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.